SCHEMBL632660

SCHEMBL632660

Nc1cccc(-n2ccnc2)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.64
MAPT P10636 2/20 0.61
LMNA P02545 1/20 0.61
CYP3A4 P08684 2/20 0.60
CYP2A6 P11509 1/20 0.55
CYP11B1 P15538 4/20 0.54
CYP11B2 P19099 4/20 0.54
CYP19A1 P11511 2/20 0.54
NCOA3 Q9Y6Q9 1/20 0.49
MEN1 O00255 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 1/20 0.49
ENPP2 Q13822 1/20 0.47
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
NOTUM Q6P988 1/20 0.47
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14489499 0.86 IDO1 (0.75) IDO1MAPTLMNACYP3A4CYP2A6
SCHEMBL872242 0.78 IDO1 (0.64) IDO1MAPTLMNACYP3A4CYP2A6
SCHEMBL3071130 0.78 IDO1 (0.64) IDO1MAPTLMNACYP3A4CYP2A6
SCHEMBL710352 0.78 IDO1 (1.00) IDO1MAPTCYP3A4CYP2A6CYP11B1
SCHEMBL10346856 0.78 IDO1 (0.64) IDO1MAPTLMNACYP3A4CYP2A6
SCHEMBL25138280 0.78 IDO1 (0.64) IDO1MAPTLMNACYP3A4CYP2A6
SCHEMBL5546083 0.78 IDO1 (0.69) IDO1MAPTLMNACYP3A4CYP2A6
SCHEMBL22114976 0.78 IDO1 (0.64) IDO1MAPTLMNACYP3A4CYP2A6
SCHEMBL21020697 0.78 IDO1 (0.64) IDO1MAPTLMNACYP3A4CYP2A6
SCHEMBL3152446 0.78 IDO1 (0.64) IDO1MAPTLMNACYP3A4CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110776657-B High-thermal-conductivity polyimide film and preparation method thereof 株洲时代华鑫新材料技术有限公司 2022-02-11 CN claimed
CN-110776657-A High-thermal-conductivity polyimide film and preparation method thereof 株洲时代新材料科技股份有限公司 2020-02-11 CN claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 US claimed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 US claimed
EP-0453731-B1 Improved process for the synthesis of N-3-(1H-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines AMERICAN CYANAMID CO (US) 1998-08-26 EP claimed
US-5064963-A CONTROLLING PH DURING REACTION AMERICAN CYANAMID COMPANY (US) 1991-11-12 US claimed
EP-0453731-A2 Improved process for the synthesis of N-3-(1H-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines AMERICAN CYANAMID COMPANY (US) 1991-10-30 EP claimed
JP-4225975-A None JP disclosed
EP-4724443-A1 PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE Acrivon Therapeutics, Inc. (US) 2026-04-15 EP disclosed
US-20250263404-A1 AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE UCL BUSINESS LTD (GB) 2025-08-21 US disclosed
WO-2024254490-A1 PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE ACRIVON THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
EP-4402127-A1 AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE UCL Business Ltd (GB) 2024-07-24 EP disclosed
US-11714080-B2 Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC (US) 2023-08-01 US disclosed
US-5064963-A CONTROLLING PH DURING REACTION AMERICAN CYANAMID COMPANY (US) 1991-11-12 US disclosed
EP-0453731-A2 Improved process for the synthesis of N-3-(1H-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines AMERICAN CYANAMID COMPANY (US) 1991-10-30 EP disclosed
EP-0453731-A2 Improved process for the synthesis of N-3-(1H-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines AMERICAN CYANAMID COMPANY (US) 1991-10-30 EP disclosed
US-4876252-A ADMINISTERING ANTIASTHMATIC OR ANTIALLERGEN AMERICAN CYANAMID COMPANY (US) 1989-10-24 US disclosed
US-4788195-A TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS AMERICAN CYANAMID COMPANY (US) 1988-11-29 US disclosed
EP-0233461-A2 4,5,6-Substituted-2-pyrimidinamines AMERICAN CYANAMID COMPANY (US) 1987-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223996-A1 IL-12 modulatory compounds IL2, IL4, IFNG IDO1 131/4885MAPT 3259/4885LMNA 4101/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 IDO1 3317/4885MAPT 1332/4885LMNA 1416/4885
US-20250263404-A1 AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE PIK3CD, PTEN, PIK3CG IDO1 2400/4885MAPT 2883/4885LMNA 3222/4885
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG IDO1 131/4885MAPT 3259/4885LMNA 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.